745 related articles for article (PubMed ID: 33032780)
1. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
[TBL] [Abstract][Full Text] [Related]
2. The use of real-world evidence to support FDA post-approval study requirements for oncology drugs.
Zettler ME
Expert Rev Anticancer Ther; 2022 Jun; 22(6):657-666. PubMed ID: 35512688
[TBL] [Abstract][Full Text] [Related]
3. Health Canada Usage of Real World Evidence (RWE) in Regulatory Decision Making compared with FDA/EMA usage based on publicly available information.
Lau C; Jamali F; Loebenberg R
J Pharm Pharm Sci; 2022; 25():227-236. PubMed ID: 35760071
[TBL] [Abstract][Full Text] [Related]
4. Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020.
Arondekar B; Duh MS; Bhak RH; DerSarkissian M; Huynh L; Wang K; Wojciehowski J; Wu M; Wornson B; Niyazov A; Demetri GD
Clin Cancer Res; 2022 Jan; 28(1):27-35. PubMed ID: 34667027
[TBL] [Abstract][Full Text] [Related]
5. The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications.
Purpura CA; Garry EM; Honig N; Case A; Rassen JA
Clin Pharmacol Ther; 2022 Jan; 111(1):135-144. PubMed ID: 34726771
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases.
Vaghela S; Tanni KA; Banerjee G; Sikirica V
Orphanet J Rare Dis; 2024 Mar; 19(1):117. PubMed ID: 38475874
[TBL] [Abstract][Full Text] [Related]
7. Understanding Use of Real-World Data and Real-World Evidence to Support Regulatory Decisions on Medical Product Effectiveness.
Mahendraratnam N; Mercon K; Gill M; Benzing L; McClellan MB
Clin Pharmacol Ther; 2022 Jan; 111(1):150-154. PubMed ID: 33891318
[TBL] [Abstract][Full Text] [Related]
8. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment.
Timbie JW; Kim AY; Concannon TW
Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277
[TBL] [Abstract][Full Text] [Related]
9. The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics.
Klonoff DC
J Diabetes Sci Technol; 2020 Mar; 14(2):345-349. PubMed ID: 30862182
[TBL] [Abstract][Full Text] [Related]
10. Oncology drug development: United States Food and Drug Administration perspective.
Hirschfeld S; Pazdur R
Crit Rev Oncol Hematol; 2002 May; 42(2):137-43. PubMed ID: 12007971
[TBL] [Abstract][Full Text] [Related]
11. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
[TBL] [Abstract][Full Text] [Related]
12. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
[TBL] [Abstract][Full Text] [Related]
13. The response rate of alternative treatments for drugs approved on the basis of response rate.
Haslam A; Gill J; Prasad V
Int J Cancer; 2021 Feb; 148(3):713-722. PubMed ID: 32700797
[TBL] [Abstract][Full Text] [Related]
14. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
15. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
Hutchinson N; Carlisle B; Doussau A; Bosan R; Gumnit E; MacPherson A; Fergusson DA; Kimmelman J
JAMA Netw Open; 2021 May; 4(5):e2110456. PubMed ID: 34003270
[TBL] [Abstract][Full Text] [Related]
16. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
17. The use of real-world data/evidence in regulatory submissions.
Song F; Zang C; Ma X; Hu S; Sun Q; Chow SC; Sun H
Contemp Clin Trials; 2021 Oct; 109():106521. PubMed ID: 34339865
[TBL] [Abstract][Full Text] [Related]
18. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
Michaeli DT; Mills M; Michaeli T; Miracolo A; Kanavos P
Invest New Drugs; 2022 Aug; 40(4):798-809. PubMed ID: 35389145
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
[TBL] [Abstract][Full Text] [Related]
20. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]